Moderna stock: Company outlines oncology strategy at Jefferies
Published on 11/18/2026 at 16:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSModerna advances its oncology strategy
- Management highlighted positive Phase III melanoma results for intismeran and plans to expand the program into additional tumor types.
- Moderna said nine randomized Phase II and Phase III studies are underway, with further readouts expected from renal, bladder and lung cancer programs.
- The company and Merck plan to share profits equally in the United States, while manufacturing preparations continue in Massachusetts.
Moderna outlined its oncology strategy around the personalized cancer vaccine candidate intismeran at the Jefferies Global Healthcare Conference on Wednesday, November 18, 2026. Investing.com reported that management presented positive Phase III melanoma results and outlined the steps needed before a potential launch.
Moderna said the melanoma study produced a hazard ratio of 0.58 in the intent-to-treat population and 0.51 among patients who received the blinded vaccine or control. Management described the result as a foundation for studies in renal cell carcinoma, bladder cancer and lung cancer.
Clinical milestones remain ahead
The company said nine randomized Phase II and Phase III studies are underway. An interim renal cell carcinoma analysis is expected within the next 12 months, final muscle-invasive bladder cancer analysis is expected in 2027, and an event-driven lung cancer readout could arrive in late 2027 or in 2028.
Moderna said more than 2,000 patients have received doses across the broader program and that the full clinical program is expected to enroll 5,000 patients. The company also highlighted a manufacturing success rate above 99% in its clinical experience.
Manufacturing and partnership structure
Management said the Marlborough, Massachusetts, facility is operating one manufacturing suite, which is intended to support an initial melanoma launch. The site can be expanded by up to six additional suites as demand develops and is designed to supply tens of thousands of patients annually at full build-out.
Moderna and Merck plan to share profits equally on the program and co-market intismeran in the United States. Merck is responsible for commercialization outside the United States. Regulatory filing, final pricing, additional clinical results and manufacturing expansion remain important milestones for investors.
Moderna stock traded at 185.00 euros on Lang & Schwarz at 16:36 CET on Wednesday, November 18.
Moderna Inc. market facts
- Company: Moderna Inc.
- ISIN: US60770K1079
- Quoted price: 185.00 euros
- Trading venue: Lang & Schwarz
- Quote time: 16:36 CET, Wednesday, November 18, 2026
Investors can follow broader US market developments through Current market reports.
